-
My Account
My Account
BSE Live
Jan 15, 15:43Prev. Close
1091.35
Open Price
1080.00
Bid Price (Qty.)
1088.40 (99)
Offer Price (Qty.)
1090.00 (31)
NSE Live
Jan 15, 16:01Prev. Close
1090.45
Open Price
1090.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1088.20 (116)
| Yearly Results of Alembic Pharmaceuticals (in Rs. Cr.) | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | |
| Net Sales/Income from operations | 4,132.55 | 3,660.27 | 2,945.26 | 2,953.16 | 2,988.19 | |
| Other Operating Income | -- | -- | -- | 3.29 | 3.55 | |
| Total Income From Operations | 4,132.55 | 3,660.27 | 2,945.26 | 2,956.45 | 2,991.74 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 978.13 | 850.05 | 725.75 | 703.87 | 642.24 | |
| Purchase of Traded Goods | 244.26 | 230.45 | 203.16 | 230.31 | 255.13 | |
| Increase/Decrease in Stocks | -176.50 | -80.41 | -36.18 | -47.90 | -95.94 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 806.37 | 684.45 | 582.72 | 527.46 | 404.31 | |
| Depreciation | 135.67 | 105.59 | 101.76 | 82.90 | 71.86 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | 216.15 | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 1,077.39 | 1,097.06 | 837.28 | 909.43 | 587.84 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 1,067.23 | 773.08 | 530.77 | 550.38 | 910.15 | |
| Other Income | 134.75 | 6.42 | 6.67 | 2.42 | 5.51 | |
| P/L Before Int., Excpt. Items & Tax | 1,201.98 | 779.50 | 537.44 | 552.80 | 915.66 | |
| Interest | 25.19 | 14.87 | 2.22 | 3.09 | 2.36 | |
| P/L Before Exceptional Items & Tax | 1,176.79 | 764.63 | 535.22 | 549.71 | 913.30 | |
| Exceptional Items | -10.00 | -- | -- | -- | -- | |
| P/L Before Tax | 1,166.79 | 764.63 | 535.22 | 549.71 | 913.30 | |
| Tax | 197.39 | 153.42 | 113.23 | 119.08 | 215.17 | |
| P/L After Tax from Ordinary Activities | 969.40 | 611.21 | 421.99 | 430.63 | 698.13 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 969.40 | 611.21 | 421.99 | 430.63 | 698.13 | |
| Equity Share Capital | 37.70 | 37.70 | 37.70 | 37.70 | 37.70 | |
| Reserves Excluding Revaluation Reserves | 3,308.32 | 2,674.71 | 2,156.93 | 1,829.62 | 1,492.58 | |
| Equity Dividend Rate (%) | 500.00 | 275.00 | 200.00 | 200.00 | 200.00 | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 51.42 | 32.42 | 22.38 | 22.84 | 37.03 | |
| Diluted EPS | 51.42 | 32.42 | 22.38 | 22.84 | 37.03 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 51.42 | 32.42 | 22.38 | 22.84 | 37.03 | |
| Diluted EPS. | 51.42 | 32.42 | 22.38 | 22.84 | 37.03 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
09.11.2020
Alembic Pharmaceuticals gets tentative USFDA nod for breast cancer treatment drug
28.10.2020
27.10.2020
Alembic Pharma Consolidated September 2020 Net Sales at Rs 1,457.10 crore, up 17.43% Y-o-Y
26.10.2020
Alembic Pharma Consolidated September 2020 Net Sales at Rs 1,457.10 crore, up 17.43% Y-o-Y
27.10.2020
Alembic Pharma Consolidated September 2020 Net Sales at Rs 1,457.10 crore, up 17.43% Y-o-Y
26.10.2020
Alembic Pharma Consolidated September 2020 Net Sales at Rs 1,457.10 crore, up 17.43% Y-o-Y
26.10.2020
Alembic Pharma Standalone September 2020 Net Sales at Rs 1,400.01 crore, up 23.36% Y-o-Y
22.10.2020
Alembic Pharma Q2 net profit up 35% at Rs 333 crore on robust sales
11.01.2019
Alembic Pharma Q3 PAT seen up 7.7% YoY to Rs. 140.6 cr: ICICI Direct
17.10.2018
Alembic Pharma Q2 PAT may dip 9.3% YoY to Rs. 110 cr: HDFC Securities
12.10.2018
Alembic Pharma Q2 PAT may dip 4.5% YoY to Rs. 116.1 cr: ICICI Direct
23.04.2018
Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey
